To see the effect of Trikatu churna and life style modification in Sthaulya(obesity)

A randomized placebo controlled clinical trial to evaluate the efficacy of â??Trikatu Churnaâ?? and lifestyle modification in the management of Sthaulya w.s.r. to Obesity.

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/04/018813

Enrollment

Registered

2019-04-26

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E660- Obesity due to excess calories

Interventions

Intervention1: TRIKATU CHURNA : Trikatu churna is a herbal formulation indicated for treatment of Obesity. It will be given in dose of 1.5 gms (3 Capsules each of 500 mgs) twice a day before lunch and

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients having age between 18 â?? 70 years of either sex. 2. Patient willing to sign the consent form. 3. The patients between the age group of 18 to 70 years of either sex presenting with clinical features of Sthaulya (obesity). 4. Patients having BMI 25-30 Kg/M2.

Exclusion criteria

Exclusion criteria: 1. Age below 18 and above 70 years. 2. Patients with complicated and chronic disorder like nephrotic syndrome, hypothyroidism, jaundice, hepatitis, chronic infections and other serious diseases. 3. Patient having BMI below 25 and more than 30. 4. Patients having Obesity due to secondary causes such as drug induced or hormonal imbalance like contraceptive pills. 5. Pregnant women and lactating mother. 6. • Patients suffering from type 1 Diabetes mellitus and uncontrolled diabetes mellitus & uncontrolled hypertension. 7. Systemic illness like Tuberculosis, Carcinoma and Endocrine disorders like Cushing syndrome, Hypothyroidism. 8. Patient having the past history of M.I. & Unstable Angina. 9. Patient having Clinical Features of CCF. 10. Patient having the major renal or liver disorder.

Design outcomes

Secondary

Measure	Time frame
1. Reduction in risk of type 2 diabetes mellitus (Will be assessed by fasting blood sugar level). 2. Reduction in Cardiac risk (will be assessed by FRAMINGHMS 10 years cardiac risk score. Timepoint: 8 weeks	—

Primary

Measure	Time frame
â?¢Changes in BMI and BMI Prime. â?¢Changes in anthropometric parameters. â?¢Changes in skin folds thickness. â?¢Changes in lipid profile. Timepoint: 8 weeks	—

Countries

India

Contacts

Public ContactDr Kiran Krishniya

National Institute of Ayurveda

joshirk1964@gmail.com9414322297

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026